NRG Therapeutics Ltd: NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson's and ALS
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studiesDeveloping a pipeline of